Market Forecasts: Seasonal Influenza Vaccines - Broadened recommendations and increased awareness boost sales in the seasonal influenza vaccine market

Introduction

Abstract

Introduction

The large public attention associated with the influenza A (H1N1, swine flu) pandemic in 2009 increased awareness of the importance of seasonal influenza vaccination. Datamonitor predicts that the seasonal influenza vaccine market will grow to $4.7bn by 2021/22, and will be driven by changes in national recommendations to include additional target populations, particularly children.

Features and benefits

• Quantifies the predicted number of people eligible for seasonal influenza vaccination across the seven major markets.
• Provides detailed sales forecasts for each of the seven major markets based on the expected coverage rates for different population groups.
• Explains the major growth drivers in the seasonal influenza vaccine market, including predicted changes to national recommendations.
• Identifies which markets provide the greatest opportunity for growth.

Highlights

Over the forecast period, the seasonal influenza vaccine market in the seven major markets is set to increase from combined sales of $3.6bn in 2011/12 to $4.7bn in 2021/22. Growth is driven by a broadening of recommendations across the seven major markets and by increased awareness of the benefits of influenza vaccination.

The US is the largest single market for influenza vaccines, and growth has been driven by price increases, increased coverage rates after the 2009 influenza pandemic, and the introduction of a universal recommendation in 2010. Campaigning by US authorities will continue to increase coverage rates; however, growth is expected to slow.

Datamonitor predicts that each of the five major EU markets will include children aged <5 years and school-aged children of 5 - 17 years in their national recommendations, substantially increasing the number of people eligible for vaccination during the forecast period.

Your key questions answered

• How was the seasonal influenza vaccine market affected by the 2009 influenza A (H1N1, swine flu) pandemic?
• Which countries are predicted to broaden recommendations for influenza vaccination over the next 10 years?
• How many people are eligible for influenza vaccination in each of the seven major markets?
• How will sales in seasonal influenza vaccines evolve for each market during the forecast period?
• Which of the seven major markets provides the greatest opportunity for growth?

Table of Contents

Table of Contents

OVERVIEW

• Catalyst
• Summary

EXECUTIVE SUMMARY

• Strategic scoping and focus
• Datamonitor key findings
• Related reports

MARKET DEFINITION

• Market definition for this disease
• Forecast methodology and assumptions

MARKET OVERVIEW AND CONTEXT

• Current and future market dynamics overview
  • Vaccination recommendations in the seven major markets
  • Vaccination coverage rates in the seven major markets
  • Seven major markets influenza vaccine forecast, 2012/13 - 2021/22

US INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• US influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

JAPAN INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• Japan influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

UK INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• UK influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

GERMANY INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• Germany influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

FRANCE INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• France influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

ITALY INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• Italy influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

SPAIN INFLUENZA VACCINE MARKET AND FORECAST

• Current market assessment
• Vaccination recommendations
• Vaccination coverage rates - historical perspective
• Spain influenza vaccine forecast
  • Forecast assumptions
  • Vaccination coverage rates - forecast
  • Influenza vaccine forecast, 2012/13 - 2021/22

BIBLIOGRAPHY

• Journal papers
• National formularies
• Websites

APPENDIX

• PharmaVitae Explorer database
• Forecast methodology
  • Datamonitor's patient-based forecasting model

TABLES

• Table: Recommendations for influenza vaccination by national authorities, 2011/12
• Table: Predicted broadening of national recommendations to include key target groups in the seven major markets, 2012
• Table: Seasonal influenza vaccine market forecast, seven major markets ($m), 2011/12 - 2021/22
• Table: Currently marketed seasonal influenza vaccines, US, 2011/12
• Table: Seasonal influenza vaccine recommendations in key target groups, US, 2012
• Table: Seasonal influenza vaccine market forecast, US, 2011/12 - 2021/22
• Table: Seasonal influenza vaccine recommendations in key target groups, Japan, 2012
• Table: Seasonal influenza vaccine market forecast, Japan, 2011/12 - 2021/22
• Table: Influenza vaccine prices per dose, UK, 2012
• Table: Seasonal influenza vaccine recommendations in key target groups, UK, 2012
• Table: Seasonal influenza market forecast, UK, 2011/12 - 2021/22
• Table: Influenza vaccine prices per dose, Germany, 2008 - 12
• Table: Seasonal influenza vaccine recommendations in key target groups, Germany, 2012
• Table: Seasonal influenza market forecast, Germany, 2011/12 - 2021/22
• Table: Influenza vaccine prices per dose, France, 2008 - 12
• Table: Seasonal influenza vaccine recommendations in key target groups, France, 2012
• Table: Seasonal influenza market forecast, France, 2011/12 - 2021/22
• Table: Influenza vaccine prices per dose, Italy, 2008 - 12
• Table: Seasonal influenza vaccine recommendations in key target groups, Italy, 2012
• Table: Seasonal influenza market forecast, Italy, 2011/12 - 2021/22
• Table: Influenza vaccine prices per dose, Spain, 2011
• Table: Seasonal influenza vaccine recommendations in key target groups, Spain, 2012
• Table: Seasonal influenza market forecast, Spain, 2011/12 - 2021/22

FIGURES

• Figure: Patient-based forecasting methodology for seasonal influenza vaccines, 2012
• Figure: Seasonal influenza vaccine market, seven major markets, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine coverage rates by age group, US, 2007/08 - 2011/12
• Figure: Seasonal influenza vaccine coverage rates by target group, US, 2007/08 - 2010/11
• Figure: Vaccination coverage by recommended age group and risk group, US, 2007/08 - 2021/22
• Figure: Vaccinated persons compared to the population recommended for the seasonal influenza vaccine, US, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market size, US, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine coverage rates for elderly aged 65 years and over, Japan, 2001/02 - 2010/11
• Figure: Vaccination coverage by recommended risk group, Japan, 2007/08 - 2021/22
• Figure: Number of vaccinated persons compared to the population recommended for the seasonal influenza vaccine, Japan, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market, Japan, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine coverage rates for recommended population groups, UK, 2007/08 - 2011/12
• Figure: Vaccination coverage by recommended risk group, UK, 2007/08 - 2021/22
• Figure: Number of vaccinated persons compared to the population recommended for the seasonal influenza vaccine, UK, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market size, UK, 2007/08 - 2021/22
• Figure: Vaccination coverage by recommended risk group, Germany, 2007/08 - 2021/22
• Figure: Number of vaccinated persons compared to the population recommended for the seasonal influenza vaccine, Germany, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market size, Germany, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine coverage rates for the elderly and healthcare workers, France, 2007/08 - 2011/12
• Figure: Vaccination coverage by recommended risk group, France, 2007/08 - 2021/22
• Figure: Number of vaccinated persons compared to the population recommended for the seasonal influenza vaccine, France, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market size, France, 2007/08 - 2021/22
• Figure: Vaccination coverage by recommended risk group, Italy, 2007/08 - 2021/22
• Figure: Number of vaccinated persons compared to the population recommended for the seasonal influenza vaccine, Italy, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market size, Italy, 2007/08 - 2021/22
• Figure: Vaccination coverage by recommended risk group, Spain, 2007/08 - 2021/22
• Figure: Number of vaccinated persons compared to the population recommended for the seasonal influenza vaccine, Spain, 2007/08 - 2021/22
• Figure: Seasonal influenza vaccine market size, Spain, 2007/08 - 2021/22
• Figure: The PharmaVitae Explorer

Market Forecasts: Seasonal Influenza Vaccines - Broadened recommendations and increased awareness boost sales in the seasonal influenza vaccine market published by Datamonitor in August 29, 2012. This report consists of Pages: 86 and the price starts from US $ 11400.